据天眼查APP显示，瑞康医药集团股份有限公司成立于2004年09月21日，注册资本150471.0471万人民 币。（数据宝） 近日该股表现 瑞康医药盘中涨停，已连收3个涨停板，截至9:35，该股报4.26元，换手率5.37%，成交量7333.23万股， 成交金额3.03亿元，涨停板封单金额为2.95亿元。连续涨停期间，该股累计上涨33.13%，累计换手率为 37.66%。最新A股总市值达64.10亿元，A股流通市值58.17亿元。 证券时报·数据宝统计，两融数据来看，该股最新（12月4日）两融余额为2.32亿元，其中，融资余额 2.31亿元，较前一个交易日增加2936.54万元，环比增长14.53%，近3日累计增加1317.02万元，环比增长 6.03%。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日涨幅偏离值达7%上榜龙虎榜1 次，买卖居前营业部中，机构净卖出2188.28万元，营业部席位合计净卖出1077.88万元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.04 | 9 ...

Group 1 - The core viewpoint of the news is that Huaren Health has shown a mixed performance in terms of financing and stock trading, with a notable increase in revenue and profit year-on-year [1][2] Group 2 - On December 4, Huaren Health's stock price increased by 0.91%, with a trading volume of 848 million yuan [1] - The financing data indicates that on the same day, Huaren Health had a financing buy amount of 85.66 million yuan and a financing repayment of 86.13 million yuan, resulting in a net financing outflow of 465,100 yuan [1] - As of December 4, the total balance of margin trading for Huaren Health was 158 million yuan, accounting for 6.40% of its market capitalization, which is above the 90th percentile of the past year [1] - In terms of securities lending, Huaren Health had no shares sold or repaid on December 4, indicating a low level of short selling activity [1] Group 3 - As of September 30, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period, while the average circulating shares per person increased by 29.64% to 7,422 shares [2] - For the period from January to September 2025, Huaren Health achieved an operating income of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, up 45.21% year-on-year [2] Group 4 - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder of Huaren Health, holding 2.3203 million shares, an increase of 1.3357 million shares from the previous period [3]

财信证券认为，周二，A股大盘全天弱势震荡，成交量缩量，反映出当前资金追高意愿有限，市场风险 偏好仍有待提升。不过三大指数仍然处于5日均线和10日均线之上，短期修复性行情未出现趋势性变 化。因此从当日走势来看，短期大盘暂时不具备连续放量上攻的动力，或将维持震荡反弹趋势。中期来 看，随着机构资金逐步开始布局2026年方向、美联储降息靴子落地、"AI投资泡沫"担忧阶段性消退，A 股市场或将迎来新一轮做多窗口期。 中原证券认为，周二，A股市场全天震荡走低。盘中船舶制造、医药商业、消费电子以及煤炭等行业表 现较好；贵金属、能源金属、生物制品以及软件开发等行业表现较弱。经过前期的快速波动之后，上周 A股市场逐步企稳回升。中长期看，支撑本轮A股上涨的基础并未发生转变。预计上证指数围绕4000点 附近蓄势整固的可能性较大，市场风格再平衡仍将延续，周期与科技有望轮番表现。 东莞证券认为，周二，A股全天震荡调整，三大指数集体下挫。海外方面，美国供应管理协会周一公布 的数据显示，全美制造业整体景气度进一步下滑，连续第九个月跌破荣枯线。A股市场方面，当前市场 整体呈现高位震荡调整格局，资金分歧有所加大，叠加国际局势不确定性和AI板块 ...

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative price increase exceeding 20% over two consecutive trading days on December 3 and 4, 2025 [1] Summary by Relevant Sections - **Stock Performance** The company's stock price increased by over 20% in total during the specified trading days, indicating significant market activity [1] - **Self-Examination and Verification** The company conducted a self-examination and confirmed that there was no need to correct or supplement previously disclosed information. No undisclosed significant information was found in media reports [1] - **Operational Status** The company's production and operations are reported to be normal, with no significant matters that should have been disclosed but were not [1] - **Insider Trading** During the period of abnormal fluctuation, the controlling shareholders did not engage in buying or selling the company's stock, and there were no violations of fair information disclosure regulations [1] - **Investor Advisory** The company advised investors to make rational investment decisions and to be aware of potential risks [1]

格隆汇12月4日丨重药控股(000950.SZ)公布，2025年前三季度利润分配预案：公司拟以2025年9月30日 享有利润分配权的股本总数1,712,778,096股（总股本1,728,184,696股扣除公司回购专户中持有的股份 15,406,600股）为基数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为51,383,342.88 元（含税），不送红股，不以公积金转增股本。 ...

近半年该股累计上榜龙虎榜14次，上榜次日股价平均跌0.88%，上榜后5日平均跌2.02%。 人民同泰(600829)今日跌停，全天换手率11.22%，成交额8.63亿元，振幅7.37%。龙虎榜数据显示，营 业部席位合计净卖出5105.98万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.96%上榜，营业部席位合计净卖出5105.98万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.77亿元，其中，买入成交额为6313.31 万元，卖出成交额为1.14亿元，合计净卖出5105.98万元。 具体来看，第一大买入营业部及卖出营业部均为中信证券股份有限公司上海分公司，买入金额为 1770.34万元，卖出金额为3926.93万元。 1021.18 资金流向方面，今日该股主力资金净流出4921.21万元，其中，特大单净流出2410.07万元，大单资金净 流出2511.14万元。近5日主力资金净流入8701.70万元。 10月21日公司发布的三季报数据显示，前三季度公司共实现营业收入78.46亿元，同比增长2.19%，实现 净利润1.12亿元，同比下降45.69%。（数据宝） 人民同泰12月4日交 ...

格隆汇12月4日丨重药控股(000950.SZ)公布，2025年前三季度利润分配预案：公司拟以2025年9月30日 享有利润分配权的股本总数1,712,778,096股（总股本1,728,184,696股扣除公司回购专户中持有的股份 15,406,600股）为基数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为51,383,342.88 元（含税），不送红股，不以公积金转增股本。 ...

格隆汇12月4日｜重药控股公告，公司拟以2025年9月30日享有利润分配权的股本总数17.13亿股为基 数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为5138.33万元（含税），不送红 股，不以公积金转增股本。 ...

编号：2025-011 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 参与单位： 东吴证券、易方达 | | 活动参与人员 | 上市公司接待人员： | | | 董事会秘书 邱天 | | | 公司 团队工作人员 IR | | 时间 | 年 月 日下午 2025 12 4 | | 地点 | 公司会议室 | | 形式 | 线上会议 | | | 1.公司 2025 年三季度经营情况如何？ | | | 答：2025 年三季度公司经营稳步向上，营业收入 亿 622.11 | | | 元，同比增长 4.22%；归母净利润 3.84 亿元，同比增长 31.41%； | | | 扣非归母净利润 亿元，同比增长 36.83%。实现营收、利润 3.79 | | | 双增长，公司管理层对公司长期发展充满信心，将聚焦于公司经 | | 交流内容及具体问 | 营与战略落地。 | | 答记录 | 2.公司进入通用技术集团后有哪些变化？ | | | ...

Core Viewpoint - 瑞康医药's stock experienced a significant increase, reaching the daily limit with a turnover rate of 24.58% and a transaction volume of 1.282 billion yuan, indicating strong market interest and volatility [2]. Trading Activity - The stock's price rose by 10.10%, leading to its inclusion on the Shenzhen Stock Exchange's watchlist for significant price deviation [2]. - Institutional investors net sold 22.4579 million yuan, while total net selling from brokerage seats amounted to 6.3127 million yuan [2]. - The top five brokerage seats accounted for a total transaction volume of 208 million yuan, with buying amounting to 89.6331 million yuan and selling at 118 million yuan, resulting in a net sell of 28.7706 million yuan [2]. Fund Flow - The stock saw a net outflow of 88.0528 million yuan from major funds, with large orders contributing to a net outflow of 53.1893 million yuan and big orders at 34.8636 million yuan [2]. - Over the past five days, the stock experienced a net inflow of 53.4196 million yuan [2]. Margin Trading - As of December 3, the margin trading balance for 瑞康医药 was 203 million yuan, with a financing balance of 202 million yuan and a securities lending balance of 484.7 thousand yuan [2]. - In the last five days, the financing balance decreased by 20.2736 million yuan, representing a decline of 9.12%, while the securities lending balance increased by 55.3 thousand yuan, showing a rise of 12.89% [2].